Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy
Public ClinicalTrials.gov record NCT01939223. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Study identification
- NCT ID
- NCT01939223
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Regorafenib (Stivarga, BAY73-4506) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1, 2013
- Primary completion
- Aug 28, 2016
- Completion
- Aug 28, 2016
- Last update posted
- Oct 19, 2017
2013 – 2016
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Laguna Hills | California | 92653 | — |
| Not listed | Los Angeles | California | 90033 | — |
| Not listed | Los Angeles | California | 90089 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | New Haven | Connecticut | 06520-8064 | — |
| Not listed | New Orleans | Louisiana | 70121 | — |
| Not listed | Baltimore | Maryland | 21201-1595 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | Omaha | Nebraska | 68106 | — |
| Not listed | New Brunswick | New Jersey | 08903-2681 | — |
| Not listed | Buffalo | New York | 14263-0001 | — |
| Not listed | New York | New York | 10021 | — |
| Not listed | Syracuse | New York | 13210 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Chattanooga | Tennessee | 37421 | — |
| Not listed | Germantown | Tennessee | 38138 | — |
| Not listed | Dallas | Texas | 75390 | — |
| Not listed | Richmond | Virginia | 23298-0037 | — |
| Not listed | Kirkland | Washington | 98034 | — |
| Not listed | Seattle | Washington | 98101 | — |
| Not listed | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01939223, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2017 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01939223 live on ClinicalTrials.gov.